This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Click here for VELSIPITY▼ (etrasimod) Prescribing Information. Adverse event reporting can be found at the bottom of the page.
Menu
Close
VELSIPITY is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.1
ELEVATE UC 52
ELEVATE UC 12
Tab Number 3
Tab Number 4
Tab Number 5
Adapted from Sandborn WJ et al. 2023 (supplementary appendix).2
Clinical remission was controlled for multiplicity via parallel gatekeeping procedures that preserved the type I error rate at 5%.3
*Clinical remission was defined as a stool frequency subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal bleeding subscore of 0, and an endoscopy score ≤1 (excluding friability).1
CI - confidence interval; JAKi - janus kinase inhibitor.
Adapted from Sandborn WJ et al. 2023 (supplementary appendix).2
Clinical remission was controlled for multiplicity via parallel gatekeeping procedures that preserved the type I error rate at 5%.3
*Clinical remission was defined as a stool frequency subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal
bleeding subscore of 0, and an endoscopy score ≤1 (excluding friability).1
Read about clinical remission with VELSIPITY among induction responders in a post hoc analysis.
Adapted from Sandborn WJ et al. 2023 (supplementary appendix).2
*Clinical remission was defined as a stool frequency subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal bleeding subscore of 0, and an endoscopy score ≤1 (excluding friability).1
CI - confidence interval; JAKi - janus kinase inhibitor.
Adapted from Sandborn WJ et al. 2023 (supplementary appendix).2
*Clinical remission was defined as a stool frequency subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal bleeding subscore of 0, and an endoscopy score ≤1 (excluding friability).1
Read about clinical remission with VELSIPITY among induction responders in a post hoc analysis.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024